Analgesia in patients with ESRD: A review of available evidence

American Journal of Kidney Diseases

Volumn 42, Issue 2, 2003, Pages 217-228

  Kurella, Manjula ^b   Bennett, William M ^b   Chertow, Glenn M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Chronic kidney disease (CKD); End stage renal disease (ESRD); Narcotic analgesics; Nonsteroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; CARBAMAZEPINE; CELECOXIB; CODEINE; DESIPRAMINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; INDOMETACIN; LAMOTRIGINE; METHADONE; MORPHINE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; PARACETAMOL; PETHIDINE; PIROXICAM; ROFECOXIB; SULINDAC; TRAMADOL; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; DRUG SENSITIVITY; EDEMA; FATIGUE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY PAIN; LIVER CIRRHOSIS; LIVER TOXICITY; META ANALYSIS; NAUSEA; NEPHROTIC SYNDROME; NEUROTOXICITY; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SIDE EFFECT; STOMACH MUCOSA LESION; UREMIA; VOMITING; XEROSTOMIA;

EID: 0041488815     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00645-0     Document Type: Article

References (96)

1. Jacox A, Carr DB, Payne R: New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med 330:651-655, 1994
2. Botting RM: Mechanism of action of acetaminophen: Is there a cyclooxygenase 3? Clin Infect Dis 31:S202-S210, 2000 (suppl 5)
3. Chandrasekharan NV, Dai H, Roos KL, et al: From the cover: COX-3, a cyclooxygenase-I variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci U S A 99:13926-13931, 2002
4. Whitcomb DC, Block GD: Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 272:1845-1850, 1994
5. FDA issues acetaminophen warning. Med Lett CDC FDA 8, 2002
6. Henrich WL, Agodoa LE, Barrett B, et al: Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 27:162-165, 1996
7. Sandler DP, Smith JC, Weinberg CR, et al: Analgesic use and chronic renal disease. N Engl J Med 320:1238-1243, 1989
8. Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziano JM: Analgesic use and renal function in men. JAMA 286:315-321, 2001
9. Fored CM, Ejerblad E, Lindblad P, et al: Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345:1801-1808, 2001
10. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal antiinflammatory drugs. Am J Med 104:413-421, 1998
11. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB: Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 43:4-13, 2000
12. Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929-1933, 1999
13. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255, 2000
14. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959, 2001
15. Whelton A: Nephrotoxicity of nonsteroidal antiinflammatory drugs: Physiologic foundations and clinical implications. Am J Med 106:S13-S24, 1999 (suppl 5B)
16. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153:477-484, 1993
17. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure?: A meta-analysis. Ann Intern Med 121:289-300, 1994
18. Canada-USA (CAN USA) Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 7:198-207, 1996
19. Shemin D, Bostom AG, Laliberty P, Dworkin LD: Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38:85-90, 2001
20. Tau SY, Shapiro R, Kish MA: Reversible acute renal failure induced by indomethacin. JAMA 241:2732-2733, 1979
21. Kimberly RP, Bowden RE, Keiser HR, Plotz PH: Reduction of renal function by newer nonsteroidal antiinflammatory drugs. Am J Med 64:804-807, 1978
22. Lifschitz MD: Renal effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 102:313-323, 1983
23. Carmichael J, Shankel SW: Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992-1000, 1985
24. Whelton A, Stoul RL, Spilman PS, Klassen DK: Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: A prospective, randomized, crossover comparison. Ann Intern Med 112:568-576, 1990
25. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504-2510, 1994
26. Rossat J, Maillard M, Nussberger J, Brunner HR. Burnier M: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66:76-84, 1999
27. Swan SK, Rudy DW, Lasseter KC, et al: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomized, controlled trial. Ann Intern Med 133:1-9, 2000
28. Frishman WH: Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 89:18D-25D, 2002
29. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM: Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8:85-95, 2001
30. Dayer P, Callart L, Desmeules J: The pharmacology of tramadol. Drugs 47:S3-S7, 1994 (suppl 1)
31. Cicero TJ, Adams EH, Geller A, et al: A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 57:7-22. 1999
32. Mason PJ, Morris VA, Balcezak TJ: Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 79:201-209, 2000
33. Lee CR, McTavish D, Sorkin EM: Tramadol: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46:313-340, 1993
34. Desmeules JA: The tramadol option. Eur J Pain 4:S15-S21, 2000 (suppl A)
35. Gardner JS, Blough D, Drinkard CR, et al: Tramadol and seizures: A surveillance study in a managed care population. Pharmacotherapy 20:1423-1431, 2000
36. Barnung SK, Treschow M, Borgbjerg FM: Respiratory depression following oral tramadol in a patient with impaired renal function. Pain 71:111-112, 1997
37. Miller RR: Clinical effects of parenteral narcotics in hospitalized medical patients. J Clin Pharmacol 20:165-171, 1980
38. Chan GL, Matzke GR: Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 21:773-783, 1987
39. Don HF, Dieppa RA, Taylor P: Narcotic analgesics in anuric patients. Anesthesiology 42:745-747, 1975
40. Bigler D, Eriksen J, Christensen CB: Prolonged respiratory depression caused by slow release morphine. Lancet 1:1477, 1984
41. Osborne R, Joel S, Grebenik K, Trew D, Slevin M: The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 54:158-167, 1993
42. Guay DR, Awni WM, Findlay JW, et al: Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 43:63-71, 1988
43. Levine DF: Hypocalcaemia increases the narcotic effect of codeine. Postgrad Med J 56:736-737, 1980
44. Matzke GR, Chan GL, Abraham PA: Codeine dosage in renal failure. Clin Pharm 5:15-16, 1986
45. Barnes JN, Goodwin FJ: Dihydrocodeine narcosis in renal failure. Br Med J 286:438-439, 1983
46. Redfern N: Dihydrocodeine overdose treated with naloxone infusion. Br Med J 287:751-752. 1983
47. Kirvela M, Lindgren L, Seppala T, Olkkola KT: The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13-18, 1996
48. Segal A, Dowling JP, Ireton HJ, et al: Granulomatous glomerulonephritis in intravenous drug users: A report of three cases in oxycodone addicts. Hum Pathol 29:1246-1249, 1998
49. Hill P. Dwyer K, Kay T, Murphy B: Severe chronic renal failure in association with oxycodone addiction: A new form of fibrillary glomerulopathy. Hum Pathol 33:783-787, 2002
50. Kalb C: Painkiller crackdown: Together with a drug company, the DEA is taking unconventional steps to stop the abuse of OxyContin. Newsweek 38, 2001
51. Stanski DR, Greenblatt DJ, Lowenstein E: Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther 24:52-59, 1978
52. Nordberg G, Borg L, Hedner T, Mellstrand T: CSF and plasma pharmacokinetics of intramuscular morphine. Eur J Clin Pharmacol 27:677-681, 1985
53. Sawe J: High-dose morphine and methadone in cancer patients: Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 11:87-106, 1986
54. Angst MS, Buhrer M, Lotsch J: Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action. Anesthesiology 92:1473-1476, 2000
55. Fainsinger R, Schoeller T, Boiskin M, Bruera E: Palliative care round: Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 9:53-55, 1993
56. Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 10:184-186, 1995
57. Lee MA, Leng ME, Tiernan EJ: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 15:26-34, 2001
58. Miller RR, Jick H: Clinical effects of meperidine in hospitalized medical patients. J Clin Pharmacol 18:180-189, 1978
59. Kaiko RF, Foley KM, Grabinski PY, et al: Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 13:180-185, 1983
60. Reutens DC, Stewart-Wynne EG: Norpethidine induced myoclonus in a patient with renal failure. J Neurol Neurosurg Psychiatry 52:1450-1451, 1989
61. Stock SL, Catalano G, Catalano MC: Meperidine associated mental status changes in a patient with chronic renal failure. J Fla Med Assoc 83:315-319, 1996
62. Hassan H, Bastani B, Gellens M: Successful treatment of normeperidine neurotoxicity by hemodialysis. Am J Kidney Dis 35:146-149, 2000
63. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M: Methadone use in patients with chronic renal disease. Drug Alcohol Depend 5:197-205, 1980
64. Nickander R, Smits SE, Steinberg MI: Propoxyphene and norpropoxyphene: Pharmacologic and toxic effects in animals. J Pharmacol Exp Ther 200:245-253, 1977
65. Giacomini KM, Gibson TP, Levy G: Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients. Clin Pharmacol Ther 27:508-514, 1980
66. Almirall J, Montoliu J, Torras A, Revert L: Propoxyphene-induced hypoglycemia in a patient with chronic renal failure. Nephron 53:273-275, 1989
67. Rose PG, Macfee MS, Boswell MV: Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg 77:390-391, 1993
68. Scholz J, Steinfath M, Schulz M: Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: An update. Clin Pharmacokinet 31:275-292, 1996
69. Koehntop DE, Rodman JH: Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 17:746-752, 1997
70. Davies G, Kingswood C, Street M: Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 31:410-422, 1996
71. Bastani B, Jamal JA: Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant 12:2802-2804, 1997
72. Blum RA, Comstock TJ, Sica DA, et al: Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56:154-159, 1994
73. Wong MO, Eldon MA, Keane WF, et al: Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 35:622-626. 1995
74. Bassilios N, Launay-Vacher V, Khoury N, Rondeau E, Deray G, Sraer JD: Gabapentin neurotoxicity in a chronic haemodialysis patient. Nephrol Dial Transplant 16:2112-2113, 2001
75. Jones H, Aguila E, Farber HW: Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. Ann Intern Med 137:74, 2002
76. Backonja M, Beydoun A, Edwards KR, et al: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 280:1831-1836, 1998
77. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159:1931-1937, 1999
78. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 280:1837-1842, 1998
79. Thorp ML, Morris CD, Bagby SP: A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 38:104-108, 2001
80. Campbell FG, Graham JG, Zilkha KJ: Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 29:265-267, 1966
81. Nicol CF: A four year double-blind study of Tegretol in facial pain. Headache 9:54-57, 1969
82. McCleane GJ: Lamotrigine in the management of neuropathic pain: A review of the literature. Clin J Pain 16:321-326, 2000
83. Lieberman JA, Cooper TB, Suckow RF, et al: Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 37:301-307, 1985
84. Niemann JT, Bessen HA, Rothstein RJ, Laks MM: Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity. Am J Cardiol 57:1154-1159, 1986
85. Parker RK, Holtmann B, White PF: Patient-controlled analgesia: Does a concurrent opioid infusion improve pain management after surgery? JAMA 266:1947-1952, 1991
86. Hansen LA, Noyes MA, Lehman ME: Evaluation of patient-controlled analgesia (PCA) versus PCA plus continuous infusion in postoperative cancer patients. J Pain Symptom Manage 6:4-14, 1991
87. Jamal JA, Joh J, Bastani B: Removal of morphine with the new high-efficiency and high-flux membranes during haemofiltration and haemodialfiltration. Nephrol Dial Transplant 13:1535-1537, 1998
88. Agodoa L: United States Renal Data System (USRDS). Nefrologia 20:S13-S16, 2002 (suppl 5)
89. Leipzig RM, Cumming RG, Tinetti ME: Drugs and falls in older people: A systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 47:40-50, 1999
90. Griffin MR, Ray WA, Schaffner W: Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 109:359-363, 1988
91. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA: Nonsteroidal anti-flammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114:257-263, 1991
92. Greenberger NJ: Update in gastroenterology. Ann Intern Med 126:221-225, 1997
93. Hawkey CJ, Karrasch JA, Szczepanski L, et al: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734, 1998
94. Yeomans ND, Tulassay Z, Juhasz L, et al: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726, 1998
95. Cohen LM, McCue JD, Germain M, Kjellstrand CM: Dialysis discontinuation: A 'good' death? Arch Intern Med 155:42-57, 1995
96. Cohen LM, Germain M, Poppel DM, Woods A, Kjellstrand CM: Dialysis discontinuation and palliative care. Am J Kidney Dis 3:140-144, 2000